These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 42866)

  • 1. [Prophylactic alkalization of the urine during cytostatic tumor treatment with the oxazaphosphorine derivatives, cyclophosphamide and ifosfamide].
    Brühl P; Hoefer-Janker H; Scheef W; Vahlensieck W
    Onkologie; 1979 Jun; 2(3):120-4. PubMed ID: 42866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.
    Andriole GL; Sandlund JT; Miser JS; Arasi V; Linehan M; Magrath IT
    J Clin Oncol; 1987 May; 5(5):799-803. PubMed ID: 3106585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bladder urotoxicity pathophysiology induced by the oxazaphosphorine alkylating agents and its chemoprevention .
    Dobrek Ł; Thor PJ
    Postepy Hig Med Dosw (Online); 2012 Sep; 66():592-602. PubMed ID: 23001201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of ifosfamide-induced hemorrhagic cystitis by continuous bladder irrigation.
    Fujita J; Matsumoto K; Kakizoe T; Murase T
    Urology; 1981 Sep; 18(3):250-1. PubMed ID: 7281389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical evaluation of Mitexan in the prevention of urinary tract complications during treatment with Holoxan].
    Czownicki Z; Utracka-Hutka B
    Nowotwory; 1981; 30(4):377-83. PubMed ID: 6792599
    [No Abstract]   [Full Text] [Related]  

  • 6. Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide.
    Brock N; Stekar J; Pohl J; Niemeyer U; Scheffler G
    Arzneimittelforschung; 1979; 29(4):659-61. PubMed ID: 114192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary elimination of cyclophosphamide alkylating metabolites and free thiols following two administration schedules of high-dose cyclophosphamide and mesna.
    Fleming RA; Cruz JM; Webb CD; Kucera GL; Perry JJ; Hurd DD
    Bone Marrow Transplant; 1996 Apr; 17(4):497-501. PubMed ID: 8722345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of cyclophosphamide-induced hemorrhagic cystitis.
    Droller MJ; Saral R; Santos G
    Urology; 1982 Sep; 20(3):256-8. PubMed ID: 7123717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The analysis of ifosfamide and its metabolites (review).
    Kaijser GP; Korst A; Beijnen JH; Bult A; Underberg WJ
    Anticancer Res; 1993; 13(5A):1311-24. PubMed ID: 8239501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [High-dose ifosfamide therapy: systemic use of a mucolytic agent for the reduction of urotoxicity].
    Marti C; Steiner R; Viollier AF
    Schweiz Med Wochenschr; 1979 Dec; 109(47):1885-7. PubMed ID: 119317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ifosfamide: chemotherapy with new promise and new problems for the urologist.
    Watson RA
    Urology; 1984 Nov; 24(5):465-8. PubMed ID: 6495457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of Advances in Uroprotective Agents for Cyclophosphamide- and Ifosfamide-induced Hemorrhagic Cystitis.
    Matz EL; Hsieh MH
    Urology; 2017 Feb; 100():16-19. PubMed ID: 27566144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urological implications of cyclophosphamide and ifosfamide.
    Lawson M; Vasilaras A; De Vries A; Mactaggart P; Nicol D
    Scand J Urol Nephrol; 2008; 42(4):309-17. PubMed ID: 18781541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The development of mesna for the inhibition of urotoxic side effects of cyclophosphamide, ifosfamide, and other oxazaphosphorine cytostatics.
    Brock N
    Recent Results Cancer Res; 1980; 74():270-8. PubMed ID: 6777836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re: Interleukin-11 attenuates ifosfamide-induced hemorrhagic cystitis.
    Gorczynska E
    Int Braz J Urol; 2007; 33(6):850-1. PubMed ID: 18199361
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: Interleukin-11 attenuates ifosfamide-induced hemorrhagic cystitis.
    Raj A; Cheerva AC; Bertolone SJ
    Int Braz J Urol; 2007; 33(6):852-3. PubMed ID: 18199362
    [No Abstract]   [Full Text] [Related]  

  • 17. Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis.
    Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):97-8. PubMed ID: 8677458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ifosfamide vs cyclophosphamide in cancer therapy.
    Weiss RB
    Oncology (Williston Park); 1991 May; 5(5):67-76; discussion 76-82, 84-6. PubMed ID: 1653004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chloroacetaldehyde and its contribution to urotoxicity during treatment with cyclophosphamide or ifosfamide. An experimental study/short communication.
    Pohl J; Stekar J; Hilgard P
    Arzneimittelforschung; 1989 Jun; 39(6):704-5. PubMed ID: 2505783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detoxification of urotoxic oxazaphosphorines by sulfhydryl compounds.
    Brock N; Pohl J; Stekar J
    J Cancer Res Clin Oncol; 1981; 100(3):311-20. PubMed ID: 6792207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.